Lyell Immunopharma, Inc. Investing Cash Flow
Lyell Immunopharma, Inc. (LYEL) reported Investing Cash Flow of $32.99 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- Lyell Immunopharma, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $15.62M, a 23.48% increase year-over-year.
- Lyell Immunopharma, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $17.38M, a 74.98% decline year-over-year.
- Lyell Immunopharma, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$31.36M, a 158.62% decline year-over-year.
- Lyell Immunopharma, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $3.35M, a 74.61% increase year-over-year.
- Lyell Immunopharma, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $54.10M, a 55.81% decline from fiscal 2024.
- Lyell Immunopharma, Inc. net cash provided by (used in) investing activities for fiscal 2024 was $122.42M, a 33.48% decline from fiscal 2023.
- Lyell Immunopharma, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $184.05M.
- Lyell Immunopharma, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$11.54M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 9 month as first filed | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $15.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $32.99M 10-Q · filed 2026-08-06 | $1.63M derived: sum of 3 quarters · filed 2026-08-06 | $4.98M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $17.38M 10-Q · filed 2026-05-06 | -$13.99M derived: sum of 2 quarters · filed 2026-05-06 | -$10.64M derived: sum of 3 quarters · filed 2026-05-06 | $2.01M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$31.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$28.02M derived: sum of 2 quarters · filed 2026-03-12 | -$15.37M derived: sum of 3 quarters · filed 2026-08-06 | $54.10M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $3.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $16.00M derived: sum of 2 quarters · filed 2026-08-06 | $85.46M 10-Q · filed 2025-11-12 | $138.97M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $12.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $82.11M 10-Q · filed 2026-08-06 | $135.62M derived: sum of 3 quarters · filed 2026-08-06 | $137.54M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $69.47M 10-Q · filed 2026-05-06 | $122.97M derived: sum of 2 quarters · filed 2026-05-06 | $124.89M derived: sum of 3 quarters · filed 2026-05-06 | $169.90M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $53.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $55.42M derived: sum of 2 quarters · filed 2026-03-12 | $100.43M derived: sum of 3 quarters · filed 2026-03-12 | $122.42M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $1.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $46.92M derived: sum of 2 quarters · filed 2025-11-12 | $68.92M 10-Q · filed 2025-11-12 | -$31.77M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-06-30 | $45.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $67.00M 10-Q · filed 2025-08-12 | -$33.69M derived: sum of 3 quarters · filed 2026-03-12 | $65.98M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-03-31 | $21.99M 10-Q · filed 2025-05-13 | -$78.70M derived: sum of 2 quarters · filed 2026-03-12 | $20.98M derived: sum of 3 quarters · filed 2026-03-12 | $173.89M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2023-12-31 | -$100.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$1.02M derived: sum of 2 quarters · filed 2026-03-12 | $151.89M derived: sum of 3 quarters · filed 2026-03-12 | $184.05M 10-K · filed 2026-03-12 | |
| 2023-09-30 | $99.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $252.58M derived: sum of 2 quarters · filed 2024-11-07 | $284.74M 10-Q · filed 2024-11-07 | $331.39M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-06-30 | $152.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $185.07M 10-Q · filed 2024-08-07 | $231.71M derived: sum of 3 quarters · filed 2025-03-11 | $174.63M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-03-31 | $32.15M 10-Q · filed 2024-05-06 | $78.80M derived: sum of 2 quarters · filed 2025-03-11 | $21.72M derived: sum of 3 quarters · filed 2025-03-11 | $46.74M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2022-12-31 | $46.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$10.44M derived: sum of 2 quarters · filed 2025-03-11 | $14.58M derived: sum of 3 quarters · filed 2025-03-11 | -$11.54M 10-K · filed 2025-03-11 | |
| 2022-09-30 | -$57.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$32.07M derived: sum of 2 quarters · filed 2023-11-07 | -$58.19M 10-Q · filed 2023-11-07 | -$132.05M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-06-30 | $25.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.10M 10-Q · filed 2023-08-08 | -$74.97M derived: sum of 3 quarters · filed 2024-02-28 | -$219.88M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | -$26.12M 10-Q · filed 2023-05-04 | -$99.98M derived: sum of 2 quarters · filed 2024-02-28 | -$244.90M derived: sum of 3 quarters · filed 2024-02-28 | -$284.37M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2021-12-31 | -$73.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$218.78M derived: sum of 2 quarters · filed 2024-02-28 | -$258.25M derived: sum of 3 quarters · filed 2024-02-28 | -$121.57M 10-K · filed 2024-02-28 | |
| 2021-09-30 | -$144.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$184.39M derived: sum of 2 quarters · filed 2022-11-08 | -$47.71M 10-Q · filed 2022-11-08 | -$47.67M 10-Q · filed 2021-11-12 | -$15.32M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$39.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $97.20M 10-Q · filed 2022-08-04 | $129.59M derived: sum of 3 quarters · filed 2023-02-28 | $39.65M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | $136.68M 10-Q · filed 2022-05-10 | $169.06M derived: sum of 2 quarters · filed 2023-02-28 | $79.12M derived: sum of 3 quarters · filed 2023-02-28 | ||
| 2020-12-31 | $32.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$57.56M derived: sum of 2 quarters · filed 2023-02-28 | -$273.52M 10-K · filed 2023-02-28 | ||
| 2020-09-30 | -$89.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$305.90M 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | -$215.96M 10-Q · filed 2021-08-12 | ||||
| 2019-12-31 | -$422.43M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |